Cargando…

Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study

BACKGROUND: Lapatinib is approved for the treatment of metastatic HER2-overexpressed breast cancer with capecitabine after progress on anthracycline, taxane, and trastuzumab in China. A post-marketing pharmacovigilance program was carried out to verify the real-world safety and the efficacy informat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Xuan, Luo, Xin, Du, Qiong, Li, Huan, Liu, Hong-Yue, Yu, Bo, Zhai, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154472/ https://www.ncbi.nlm.nih.gov/pubmed/32309387 http://dx.doi.org/10.21037/atm.2020.03.21

Ejemplares similares

Predicting Lapatinib Dose Regimen Using Machine Learning and Deep Learning Techniques Based on a Real-World Study
por: Yu, Ze, et al.
Publicado: (2022)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
por: Xie, Yizhao, et al.
Publicado: (2020)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
por: Ouyang, D. J, et al.
Publicado: (2021)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
por: Lin, Ying, et al.
Publicado: (2020)

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
por: Xu, Bing-He, et al.
Publicado: (2011)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
por: Hua, Yijia, et al.
Publicado: (2022)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
por: Xu, Zhi-qiao, et al.
Publicado: (2017)

Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation
por: Huo, Zhi-Jun, et al.
Publicado: (2015)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
por: Gong, Xiaoling, et al.
Publicado: (2022)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
por: Zhou, Bingjing, et al.
Publicado: (2022)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
por: Yuan, Ye, et al.
Publicado: (2022)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
por: Wang, Fen, et al.
Publicado: (2021)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Lapatinib for the treatment of breast cancer in the People’s Republic of China
por: Wang, Hongjiang
Publicado: (2014)

Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report
por: NOGUCHI, EIICHIRO, et al.
Publicado: (2014)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study
por: Xu, Fei, et al.
Publicado: (2020)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
por: Toi, M, et al.
Publicado: (2009)

Chemotherapy-Induced Reduction of Neutrophil-to-Lymphocyte Ratio Is Associated With Better Survival in Pancreatic Adenocarcinoma: A Meta-Analysis
por: Luo, Xin, et al.
Publicado: (2020)

Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients
por: Zhu, Linhui, et al.
Publicado: (2021)

SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer
por: Xu, Rui, et al.
Publicado: (2021)

Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
por: Thomson, Andrew
Publicado: (2005)

Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Diagnostic potential of serum exosomal colorectal neoplasia differentially expressed long non-coding RNA (CRNDE-p) and microRNA-217 expression in colorectal carcinoma
por: Yu, Bo, et al.
Publicado: (2017)

Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models
por: Ando, Kentaro, et al.
Publicado: (2020)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
por: Zheng, Hao-Ran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ell1ffprvk6bsa0p9lvvt1g7b